Lone Atrial Fibrillation Is Associated with Impaired Left Ventricular Energetics That Persists Despite Successful Catheter Ablation

Circulation

Volumn 134, Issue 15, 2016, Pages 1068-1081

  Wijesurendra, Rohan S ^a,b   Liu, Alexander ^a,b   Eichhorn, Christian ^a,b   Ariga, Rina ^a,b   Levelt, Eylem ^a,b   Clarke, William T ^a,b   Rodgers, Christopher T ^a,b   Karamitsos, Theodoros D ^a,b   Bashir, Yaver ^c   Ginks, Matthew ^c   Rajappan, Kim ^c   Betts, Tim ^c   Ferreira, Vanessa M ^a,b   Neubauer, Stefan ^a,b   Casadei, Barbara ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

arrhythmias, cardiac; atrial fibrillation; catheter ablation; magnetic resonance imaging; magnetic resonance spectroscopy; ventricular dysfunction, left

Indexed keywords

CREATINE PHOSPHATE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP);

ADULT; ARTICLE; CARDIAC IMAGING; CATHETER ABLATION; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELECTROCARDIOGRAM; ENERGY TRANSFER; FEMALE; HEART LEFT ATRIUM; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART OUTPUT; HEART STROKE VOLUME; HOLTER MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PAROXYSMAL ATRIAL FIBRILLATION; PERSISTENT ATRIAL FIBRILLATION; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; ADVERSE EFFECTS; AGED; ATRIAL FIBRILLATION; CARDIAC MUSCLE; CARDIOMYOPATHY; COMPLICATION; ECHOCARDIOGRAPHY; HEART ATRIUM; HEART FAILURE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

AGED; ATRIAL FIBRILLATION; CARDIOMYOPATHIES; CATHETER ABLATION; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIA; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84988622224     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.116.022931     Document Type: Article

References (49)

1. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB. Stroke severity in atrial fibrillation: the Framingham study. Stroke. 1996;27:1760-1764.
2. Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA, Thacker EL, Judd S, Howard VJ, Howard G, Herrington DM, Cushman M. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med. 2014;174:107-114. doi: 10.1001/ jamainternmed.2013.11912.
3. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946-952.
4. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837-847. doi: 10.1161/ CIRCULATIONAHA.113.005119.
5. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation. 1995;92:1954-1968.
6. Carnes CA, Chung MK, Nakayama T, Nakayama H, Baliga RS, Piao S, Kanderian A, Pavia S, Hamlin RL, McCarthy PM, Bauer JA, Van Wagoner DR. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res. 2001;89:E32-E38.
7. Goette A, Bukowska A, Dobrev D, Pfeiffenberger J, Morawietz H, Strugala D, Wiswedel I, Röhl FW, Wolke C, Bergmann S, Bramlage P, Ravens U, Lendeckel U. Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles. Eur Heart J. 2009;30:1411-1420. doi: 10.1093/eurheartj/ehp046.
8. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91:265-325. doi: 10.1152/physrev.00031.2009.
9. Lévy S. Epidemiology and classification of atrial fibrillation. J Cardiovasc Electrophysiol. 1998;9(suppl):S78-S82.
10. Wyse DG, Van Gelder IC, Ellinor PT, Go AS, Kalman JM, Narayan SM, Nattel S, Schotten U, Rienstra M. Lone atrial fibrillation: does it exist? J Am Coll Cardiol. 2014;63:1715-1723. doi: 10.1016/j. jacc.2014.01.023.
11. Tops LF, Den Uijl DW, Delgado V, Marsan NA, Zeppenfeld K, Holman E, van der Wall EE, Schalij MJ, Bax JJ. Long-term improvement in left ventricular strain after successful catheter ablation for atrial fibrillation in patients with preserved left ventricular systolic function. Circ Arrhythm Electrophysiol. 2009;2:249-257. doi: 10.1161/CIRCEP.108.838748.
12. Zhu P, Zhang Y, Jiang P, Wang Z, Wang J, Yin X, Hou Y. Effects of radiofrequency catheter ablation on left ventricular structure and function in patients with atrial fibrillation: a meta-analysis. J Interv Card Electrophysiol. 2014;40:137-145. doi: 10.1007/s10840-014-9903-1.
13. Wijesurendra RS, Casadei B. Atrial fibrillation: effects beyond the atrium? Cardiovasc Res. 2015;105:238-247. doi: 10.1093/cvr/ cvv001.
14. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-1840. doi: 10.1056/NEJMoa021375.
15. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833. doi: 10.1056/NEJMoa021328.
16. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667-2677. doi: 10.1056/NEJMoa0708789.
17. Hudsmith LE, Neubauer S. Magnetic resonance spectroscopy in myocardial disease. JACC Cardiovasc Imaging. 2009;2:87-96. doi: 10.1016/j.jcmg.2008.08.005.
18. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-2429.
19. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano RJ Jr, Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines DE, Haissaguerre M, Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais P, Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, Kottkamp H, Kumagai K, Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C, Prystowsky E, Raviele A, Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012;14:528-606. doi: 10.1093/europace/eus027.
20. Dodson JA, Neilan TG, Shah RV, Farhad H, Blankstein R, Steigner M, Michaud GF, John R, Abbasi SA, Jerosch-Herold M, Kwong RY. Left atrial passive emptying function determined by cardiac magnetic resonance predicts atrial fibrillation recurrence after pulmonary vein isolation. Circ Cardiovasc Imaging. 2014;7:586-592. doi: 10.1161/CIRCIMAGING.113.001472.
21. Stuber M, Spiegel MA, Fischer SE, Scheidegger MB, Danias PG, Pedersen EM, Boesiger P. Single breath-hold slice-following CSPAMM myocardial tagging. MAGMA. 1999;9:85-91.
22. Lawton JS, Cupps BP, Knutsen AK, Ma N, Brady BD, Reynolds LM, Pasque MK. Magnetic resonance imaging detects significant sex differences in human myocardial strain. Biomed Eng Online. 2011;10:76. doi: 10.1186/1475-925X-10-76.
23. Tyler DJ, Emmanuel Y, Cochlin LE, Hudsmith LE, Holloway CJ, Neubauer S, Clarke K, Robson MD. Reproducibility of 31P cardiac magnetic resonance spectroscopy at 3 T. NMR Biomed. 2009;22:405-413. doi: 10.1002/nbm.1350.
24. Dass S, Cochlin LE, Holloway CJ, Suttie JJ, Johnson AW, Tyler DJ, Watkins H, Robson MD, Clarke K, Neubauer S. Development and validation of a short 31P cardiac magnetic resonance spectroscopy protocol. J Cardiovasc Magn Reson. 2010;12:1-2.
25. Rodgers CT, Clarke WT, Snyder C, Vaughan JT, Neubauer S, Robson MD. Human cardiac 31P magnetic resonance spectroscopy at 7 Tesla. Magn Reson Med. 2014;72:304-315. doi: 10.1002/ mrm.24922.
26. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009;10:165-193. doi: 10.1093/ejechocard/jep007.
27. Faul F, Erdfelder E, Lang AG, Buchner A. G∗Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175-191.
28. Hudsmith LE, Petersen SE, Francis JM, Robson MD, Neubauer S. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J Cardiovasc Magn Reson. 2005;7:775-782.
29. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Bartoccini C, Santucci A, Santucci C, Reboldi G, Porcellati C. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol. 1995;25:871-878. doi: 10.1016/0735-1097(94)00424-O.
30. Dweck MR, Joshi S, Murigu T, Gulati A, Alpendurada F, Jabbour A, Maceira A, Roussin I, Northridge DB, Kilner PJ, Cook SA, Boon NA, Pepper J, Mohiaddin RH, Newby DE, Pennell DJ, Prasad SK. Left ventricular remodeling and hypertrophy in patients with aortic stenosis: insights from cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14:50. doi: 10.1186/1532-429X-14-50.
31. Cavassila S, Deval S, Huegen C, van Ormondt D, Graveron-Demilly D. Cramér-Rao bounds: an evaluation tool for quantitation. NMR Biomed. 2001;14:278-283.
32. Lim HS, Schultz C, Dang J, Alasady M, Lau DH, Brooks AG, Wong CX, Roberts-Thomson KC, Young GD, Worthley MI, Sanders P, Willoughby SR. Time course of inflammation, myocardial injury, and prothrombotic response after radiofrequency catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2014;7:83-89. doi: 10.1161/CIRCEP.113.000876.
33. Hsieh MH, Chiou CW, Wen ZC, Wu CH, Tai CT, Tsai CF, Ding YA, Chang MS, Chen SA. Alterations of heart rate variability after radiofrequency catheter ablation of focal atrial fibrillation originating from pulmonary veins. Circulation. 1999;100:2237-2243.
34. Reant P, Lafitte S, Jaïs P, Serri K, Weerasooriya R, Hocini M, Pillois X, Clementy J, Haïssaguerre M, Roudaut R. Reverse remodeling of the left cardiac chambers after catheter ablation after 1 year in a series of patients with isolated atrial fibrillation. Circulation. 2005;112:2896-2903. doi: 10.1161/CIRCULATIONAHA. 104.523928.
35. Kottkamp H. Fibrotic atrial cardiomyopathy: a specific disease/ syndrome supplying substrates for atrial fibrillation, atrial tachycardia, sinus node disease, AV node disease, and thromboembolic complications. J Cardiovasc Electrophysiol. 2012;23:797-799. doi: 10.1111/j.1540-8167.2012.02341.x.
36. Schotten U, Dobrev D, Platonov PG, Kottkamp H, Hindricks G. Current controversies in determining the main mechanisms of atrial fibrillation. J Intern Med. 2016;279:428-438. doi: 10.1111/ joim.12492.
37. Neubauer S. The failing heart: an engine out of fuel. N Engl J Med. 2007;356:1140-1151. doi: 10.1056/NEJMra063052.
38. Bottomley PA, Panjrath GS, Lai S, Hirsch GA, Wu K, Najjar SS, Steinberg A, Gerstenblith G, Weiss RG. Metabolic rates of ATP transfer through creatine kinase (CK Flux) predict clinical heart failure events and death. Sci Transl Med. 2013;5:215re3. doi: 10.1126/scitranslmed.3007328.
39. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation. 1997;96:2190-2196.
40. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, Bauer JA. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation. 2001;104:174-180.
41. Ausma J, Coumans WA, Duimel H, Van der Vusse GJ, Allessie MA, Borgers M. Atrial high energy phosphate content and mitochondrial enzyme activity during chronic atrial fibrillation. Cardiovasc Res. 2000;47:788-796.
42. McGann C, Akoum N, Patel A, Kholmovski E, Revelo P, Damal K, Wilson B, Cates J, Harrison A, Ranjan R, Burgon NS, Greene T, Kim D, Dibella EV, Parker D, Macleod RS, Marrouche NF. Atrial fibrillation ablation outcome is predicted by left atrial remodeling on MRI. Circ Arrhythm Electrophysiol. 2014;7:23-30. doi: 10.1161/ CIRCEP.113.000689.
43. Konrad T, Theis C, Mollnau H, Sonnenschein S, Ocete BQ, Bock K, Münzel T, Rostock T. Primary persistent atrial fibrillation: a distinct arrhythmia subentity of an ablation population. J Cardiovasc Electrophysiol. 2015;26:1289-1294. doi: 10.1111/jce.12818.
44. Kottkamp H. Human atrial fibrillation substrate: towards a specific fibrotic atrial cardiomyopathy. Eur Heart J. 2013;34:2731-2738. doi: 10.1093/eurheartj/eht194.
45. Smith CS, Bottomley PA, Schulman SP, Gerstenblith G, Weiss RG. Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation. 2006;114:1151-1158. doi: 10.1161/CIRCULATIONAHA.106.613646.
46. Hirsch GA, Bottomley PA, Gerstenblith G, Weiss RG. Allopurinol acutely increases adenosine triphosphate energy delivery in failing human hearts. J Am Coll Cardiol. 2012;59:802-808. doi: 10.1016/j.jacc.2011.10.895.
47. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, Lorimer MF, Lau DH, Antic NA, Brooks AG, Abhayaratna WP, Kalman JM, Sanders P. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310:2050-2060. doi: 10.1001/jama.2013.280521.
48. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, Alasady M, Hanley L, Antic NA, McEvoy RD, Kalman JM, Abhayaratna WP, Sanders P. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014;64:2222-2231. doi: 10.1016/j.jacc.2014.09.028.
49. Hundley WG, Meshack BM, Willett DL, Sayad DE, Lange RA, Willard JE, Landau C, Hillis LD, Peshock RM. Comparison of quantitation of left ventricular volume, ejection fraction, and cardiac output in patients with atrial fibrillation by cine magnetic resonance imaging versus invasive measurements. Am J Cardiol. 1996;78:1119-1123.